Reported attempts to treat ameloblastomas with BRAF inhibitors (BRAFi) [with/without mitogen-activated protein kinase (MEK) inhibitors (MEKi)] as a last line treatment, have been successful for seven patients with recurrent inoperable conventional ameloblastomas, even some with lung metastatic deposits [7–14]. Here, BRAF is linked to ameloblastoma.